ArticleBMC developmental biology2015
The developmental basis of mesenchymal stem/stromal cells (MSCs).
Article in BMC developmental biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 135 citations in OpenAlex.
- From hPSCs to MSCs: differentiation strategies, pathways, and the emergence of common regulatory networks.Cellular & molecular biology letters · 2026Review
- Embryonic lineage-specific iPSC-derived mesenchymal stem/stromal cells exhibit different morphologies and intrinsic functions.iScience · 2026Article
- Whispers of Growth: The Impact of MicroRNA on the Proliferation Potential of Adipose-Derived Stem Cells-A Review.BioMed research international · 2026Review
- Identification of Expression Quantitative Trait Loci (eQTL) for Adipose-Specific Regulatory Mechanisms in Hanwoo (Korean Cattle).Animals : an open access journal from MDPI · 2025Article
- Deriving the A/B Cells Policy as a Robust Multi-Object Cell Pipeline for Time-Lapse Microscopy.International journal of molecular sciences · 2025Article
- Stem Cell Therapies in Canine Cardiology: Comparative Efficacy, Emerging Trends, and Clinical Integration.Biomolecules · 2025Review
- Rethinking Biomedical Titanium Alloy Design: A Review of Challenges from Biological and Manufacturing Perspectives.Advanced healthcare materials · 2025Review
- Controlled delivery of mesenchymal stem cells via biodegradable scaffolds for fracture healing.Nanomedicine (London, England) · 2025Review
- Regenerative Therapy for Deep Burn Injury using Mesenchymal Stem Cells and Myrtle (Myrtus Communis) in a Rat Model.Current stem cell research & therapy · 2025Article
- Equine adipose-derived stem cells modulateFrontiers in veterinary science · 2025Article
- Mesenchymal stem cells and exosomes in ischemic brain injury: a review.Frontiers in genetics · 2025Review
- Derivation of Mesenchymal Stem Cells through Sequential Presentation of Growth Factors via Gelatin Microparticles in Pluripotent Stem Cell Spheroids.Biomaterials research · 2025Article
- Editorial: Biomaterials and biological regulation for bone tissue remodeling and regeneration.Frontiers in bioengineering and biotechnology · 2025Article
- Prediction of Age-Related MicroRNA Signature in Mesenchymal Stem Cells by using Computational Methods.Current stem cell research & therapy · 2025Article
- Fibroblast Heterogeneity in Inflammatory Bowel Disease.International journal of molecular sciences · 2024Review
- Article
- Sacral Bioneuromodulation: The Role of Bone Marrow Aspirate in Spinal Cord Injuries.Bioengineering (Basel, Switzerland) · 2024Review
- Differentiation of placenta-derived MSCs cultured in human platelet lysate: a xenofree supplement.3 Biotech · 2024Article
- The Role and Prospects of Mesenchymal Stem Cells in Skin Repair and Regeneration.Biomedicines · 2024Review
- Understanding host-graft crosstalk for predicting the outcome of stem cell transplantation.World journal of stem cells · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMesenchymal Stem/Stromal Cells (MSCs) define a population of progenitor cells capable of giving rises to at least three mesodermal lineages in vitro, the chondrocytes, osteoblasts and adipocytes. The validity of MSCs in vivo has been questioned because their existence, either as a homogeneous progenitor cell population or as a stem cell lineage, has been difficult to prove. The wide use of primary MSCs in regenerative and therapeutic applications raises ethical and regulatory concerns in many countries. In contrast to hematopoietic stem cells, a parallel concept which carries an embryological emphasis from its outset, MSCs have attracted little interest among developmental biologists and the embryological basis for their existence, or lack thereof, has not been carefully evaluated.
methodsThis article provides a brief, embryological overview of these three mesoderm cell lineages and offers a framework of ontological rationales for the potential existence of MSCs in vivo.
resultsEmphasis is given to the common somatic lateral plate mesoderm origin of the majority of body's adipose and skeletal tissues and of the major sources used for MSC derivation clinically. Support for the MSC hypothesis also comes from a large body of molecular and lineage analysis data in vivo.
conclusionsIt is concluded that despite the lack of a definitive proof, the MSC concept has a firm embryological basis and that advances in MSC research can be facilitated by achieving a better integration with developmental biology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.